跳至主要内容
临床试验/EUCTR2004-004984-32-IT
EUCTR2004-004984-32-IT进行中(未招募)不适用

A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressive Disorder

GLAXO SMITHKLINE0 个研究点目标入组 500 人开始时间: 2007年2月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
1 期
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.Parkinson's disease
EUCTR2005-005423-34-GBGlaxoSmithKline Research & Development Ltd
进行中(未招募)
不适用
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - NDParkinson diseaseMedDRA version: 6.1Level: PTClassification code 10061536
EUCTR2005-005423-34-ITGlaxoSmithKline R D516
进行中(未招募)
不适用
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressive Disorder
EUCTR2004-004984-32-SEGlaxoSmithKline Research and Development Limited348
已完成
3 期
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.Persistent Asthma10006436Asthma
NL-OMON34054GlaxoSmithKline62
进行中(未招募)
1 期
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.Persistent Asthma in Adults and Adolescents.MedDRA version: 12.1Level: LLTClassification code 10003553Term: Asthma
EUCTR2010-019589-10-NLGlaxoSmithKline Research & Development Ltd1,564